biotech

Bio-Analyst

Research Platform
person
arrow_backExplore/Inositol
Tier-BPublic-ready6/27/2026

Inositol

Glucose and metabolic health markers is closer to a research marker, so it should be read separately from a directly felt benefit.

The 64.4 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the B tier remains conservative.

Representative tier calculated from paper evidence that passed the collection audit.

Papers analyzed
85
Caution signal
Low
Context-specific research signal
64.4
Glucose and metabolic health markersMenstrual and women's healthMale Reproductive Health Markers

Main benefit evidence

The representative ingredient tier is calculated from these target-level evidence groups.

Glucose and metabolic health
10 studiesTier-B
Glucose and metabolic health markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
63.7
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Women's health
8 studiesTier-B
Menstrual and women's health
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.

Evidence score
61.4
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Men's health
3 studiesTier-B
Male Reproductive Health Markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

These findings come from sperm, semen, or hormone markers such as testosterone, LH, FSH, and inhibin B. They are closer to research measurements than a directly felt benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
52.0
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood lipids
3 studiesTier-B
Cholesterol and triglycerides
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.

Evidence score
52.0
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Exercise performance and recovery
1 studiesTier-C
Exercise performance and recovery
Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Exercise performance and recovery. These findings come from a defined study population, so everyday effects may differ.

Evidence score
44.0
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Cognition and focus
1 studiesTier-C
Cognition, memory, and focus
Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Cognition and focus. These findings come from a defined study population, so everyday effects may differ.

Evidence score
20.9
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Recent research

Updated This Month10 new papers

Key cautions to review

Standalone side-effect signals and combination cautions are listed separately.

Caution index
0.6
Caution band: Low
Caution signals
5
Side effects + combos + curated rules
Key precautions
No curated contraindication rule is available yet, but literature caution signals are shown below.
Standalone side effects, combination cautions, and positive combos are separated below.

Standalone side effects

ovarian histology1 papers
High doses of D-Chiro-Inositol (5-20 mg/day) administered to female mice for 21 days induced adverse ovarian histological changes and altered serum testosterone levels, suggesting toxicity rather than therapeutic benefit.animal · animal-study
oocyte quality1 papers
The review notes that high concentrations of D-chiro-inositol in the ovary may adversely affect oocyte quality.human · systematic-review
adverse events (gastrointestinal)1 papers
Myo-inositol is associated with significantly fewer adverse events compared to metformin in PCOS women, with a risk ratio of 5.17 for adverse events with metformin.human · meta-analysis
side effects of excess D-chiro-inositol1 papers
The review notes the potential for side effects associated with excess D-chiro-inositol, though specific details require further study.human · systematic-review
gastrointestinal adverse events1 papers
Myo-inositol likely causes fewer gastrointestinal adverse events compared with metformin, which are typically mild and self-limited.human · meta-analysis

Evidence summaries

Paper IDs and full lists are private. Only study types and summaries are shown.

Key Evidence #1
Public scholarly dataCitation signal: 199
observational

[Abstract]: Major depressive disorder (MDD) is a serious mental illness, characterized by high morbidity, which has increased in recent decades. However, the molecular mechanisms underlying MDD remain unclear. Previous studies have identified altered metabolic

Key Evidence #2
Public scholarly dataCitation signal: 176
review

It is timely to consider exploration of roles and applications of “other” isomers and their derivatives, likely by exploiting techniques now well developed for the myo-series.

Key Evidence #3
Public scholarly dataCitation signal: 167
observational

[Abstract]: OBJECTIVE To check the hypothesis that myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) onset in pregnant women with a family history of type 2 diabetes. RESEARCH DESIGN AND METHODS A 2-year, prospective, randomized, open

3 more summariesLimited representative sample by study type.
>
Public scholarly dataCitation signal: 133
observational

This systematic review is the analysis of recent randomized clinical trials of inositol(s) in PCOS, in particular myo- and D-chiro-inositol, in order to better elucidate their physiological involvement inPCOS and potential therapeutic use, alone and in conjunc

Public scholarly dataCitation signal: 127
observational

The trial sequential analysis of insulin meta-analysis illustrates that the cumulative z-curve crossed the monitoring boundary, providing firm evidence of the intervention effect of MI in improving the metabolic profile of women with PCOS, concomitantly reduci

Public scholarly dataCitation signal: 121
observational

In women with PCOS, increased glucose-stimulated DCI-IPG release is significantly correlated with improved insulin sensitivity, and the significant relationship between DCI-IPG release and insulin sensitivity suggests that the DCI-IPG mediator may be a target

Inositol
arrow_backBack to list